Oregovomab Biosimilar – Anti-MUC16, CA125 mAb – Research Grade

Introduction

Oregovomab Biosimilar, also known as Anti-MUC16 or CA125 mAb, is a monoclonal antibody that specifically targets the MUC16 protein. MUC16 is a cell surface glycoprotein that is overexpressed in various types of cancers, including ovarian, breast, and lung cancer. Oregovomab Biosimilar is a research grade antibody that has been extensively studied for its potential as a therapeutic agent in cancer treatment.

Structure

Oregovomab Biosimilar is a recombinant humanized monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, which are linked together by disulfide bonds. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab regions are responsible for binding to the MUC16 protein, while the Fc region is involved in immune effector functions.

Activity

The main mechanism of action of Oregovomab Biosimilar is through its binding to the MUC16 protein. MUC16 is a transmembrane protein that is overexpressed on the surface of cancer cells. By binding to MUC16, Oregovomab Biosimilar can inhibit the growth and proliferation of cancer cells. It can also induce antibody-dependent cellular cytotoxicity (ADCC), which is a process where immune cells, such as natural killer cells, recognize and kill cancer cells that are coated with the antibody.

In addition to its direct anti-

cancer activity, Oregovomab Biosimilar has also been shown to have immunomodulatory effects. It can stimulate the production of cytokines, such as interferon-gamma and interleukin-2, which play important roles in the immune response against cancer. This makes Oregovomab Biosimilar a promising candidate for combination therapy with other cancer treatments.

Application

Oregovomab Biosimilar is primarily being studied for its potential as a therapeutic agent in cancer treatment. It has shown promising results in preclinical studies and early clinical trials for the treatment of ovarian cancer. In a phase II clinical trial, Oregovomab Biosimilar was found to significantly prolong progression-free survival in patients with advanced ovarian cancer when used in combination with chemotherapy.

Apart from ovarian

cancer, Oregovomab Biosimilar has also been evaluated for its potential in other types of cancer, such as breast and lung cancer. In a phase I clinical trial, Oregovomab Biosimilar was found to be well-tolerated and showed promising results in patients with metastatic breast cancer.

In addition to its potential as a therapeutic agent, Oregovomab Biosimilar is also being studied for its diagnostic and prognostic applications. The MUC16 protein, which is the target of Oregovomab Biosimilar, is also a biomarker for various types of cancer. By detecting the levels of MUC16 in the blood, Oregovomab Biosimilar can potentially be used for early detection and monitoring of cancer.

Conclusion

Oregovomab Biosimilar, also known as Anti-MUC16 or CA125 mAb, is a recombinant humanized monoclonal antibody that specifically targets the MUC16 protein. It has shown promising results in preclinical and clinical studies for the treatment of various types of cancer, including ovarian, breast, and lung cancer. Oregovomab Biosimilar has also shown potential as a diagnostic and prognostic tool for cancer. Further research and clinical trials are needed to fully understand the potential of Oregovomab Biosimilar in cancer treatment and management.